| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $27.0M | — | +244.7% |
| SG&A Expense | $24.2M | — | +141.3% |
| Operating Income | -$51.2M | — | -186.7% |
| Pre-tax Income | -$29.9M | — | -110.3% |
| Income Tax | $3.2M | — | +171.5% |
| Net Income | -$33.1M | — | -237.1% |
| EPS (Basic) | -$0.19 | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.59B | +102.2% | +1669.7% |
| Current Assets | $2.23B | +77.5% | +986.2% |
| Total Assets | $2.70B | +76.9% | +794.8% |
| Current Liabilities | $37.1M | +45.4% | +556.7% |
| Total Liabilities | $64.9M | +24.2% | +97.7% |
| Stockholders' Equity |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.9M | — | -45.9% |
| Capital Expenditures | $32.8M | — | +9782.5% |
| Investing Cash Flow | -$359.0M | — | -6020.7% |
| Financing Cash Flow | $1.18B | — | — |
| Free Cash Flow | -$50.7M | — | -303.0% |
| -171.4% |
| EPS (Diluted) | -$0.19 | — | -171.4% |
| $2.64B |
| +78.7% |
| +879.7% |